Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mthera Pharma Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units and 2 distinct examiners. JENNIFER E GRASER is the busiest examiner, responsible for 1 pending action. This distribution shows that the company's active matters are being handled independently across different technical groups, despite both falling under the broad biotech and pharma umbrella.
The involvement of 2 distinct examiners and 2 distinct art units for the pending actions represents a degree of diversification for the portfolio. Each application is being evaluated by a different examiner in a different specialized unit, which prevents any single examiner's tendencies from affecting the entire portfolio. This structure requires the company to manage separate prosecution paths, each with its own technical requirements and examiner expectations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18734013 | COMPOSITION FOR PREVENTION OR TREATMENT OF COGNITIVE DYSFUNCTION AND INTESTINAL DYSFUNCTION, COMPRISING LACTOBACILLUS PARACASEI NK112, CUSCUTA AUSTRALIS EXTRACT, AND CUSCUTA JAPONICA EXTRACT | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18734013 | COMPOSITION FOR PREVENTION OR TREATMENT OF COGNITIVE DYSFUNCTION AND INTESTINAL DYSFUNCTION, COMPRISING LACTOBACILLUS PARACASEI NK112, CUSCUTA AUSTRALIS EXTRACT, AND CUSCUTA JAPONICA EXTRACT | GRASER, JENNIFER E | — |
| 18038524 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING INFLAMMATORY BOWEL DISEASE, COMPRISING ISATIDIS FOLIUM EXTRACT | BOECKELMAN, JACOB A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18734013 | COMPOSITION FOR PREVENTION OR TREATMENT OF COGNITIVE DYSFUNCTION AND INTESTINAL DYSFUNCTION, COMPRISING LACTOBACILLUS PARACASEI NK112, CUSCUTA AUSTRALIS EXTRACT, AND CUSCUTA JAPONICA EXTRACT | GRASER, JENNIFER E | 1645 | §101§102§112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18038524 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING INFLAMMATORY BOWEL DISEASE, COMPRISING ISATIDIS FOLIUM EXTRACT | BOECKELMAN, JACOB A | 1655 | §103 | Non-Final OA | — | Pending | May 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial